Johnson & Johnson Raises Quarterly Dividend to $1.34

Johnson & Johnson (JNJ) increased its quarterly dividend to $1.34 per share from $1.30, a 3.08% raise, with the shares trading ex-dividend on May 26, 2026.

The new payout implies an annual dividend of $5.36 per share. Based on the locked share price of $237, the forward annual yield is 2.26%. The increase extends Johnson & Johnson’s dividend-growth streak to 55 consecutive years.

Business Context

The dividend action comes as Johnson & Johnson continues to operate as a more focused health-care company following the separation of its consumer-health business, Kenvue. The company is now centered on Innovative Medicine and MedTech, a structure that has made prescription drugs, medical devices and related technology the core drivers of its business mix. The company has also moved to further sharpen that portfolio, including plans reported by the Associated Press to separate its orthopedics business, DePuy Synthes, into a standalone company.

Recent operating commentary has pointed to strength in Johnson & Johnson’s drug portfolio. MarketWatch reported that the company raised its 2026 sales and earnings outlook after a strong first quarter, citing momentum in immunology and oncology products, including Tremfya and Darzalex. That backdrop is relevant for dividend investors because recurring cash generation across large health-care franchises is a key support for established payout programs.

Johnson & Johnson remains one of the largest companies in the Healthcare sector, with a locked market capitalization of $570.51 billion. The company’s dividend safety score is 89 out of 100, with an A grade, and the locked facts show no prior dividend cut year.

What It Means for Income Investors

For income investors, the increase is incremental rather than dramatic, but it reinforces the company’s long record of annual dividend growth. The move raises the quarterly cash payout while keeping the yield in the low-single-digit range at the locked share price.

The main income takeaway is continuity: Johnson & Johnson is pairing a modest payout increase with a business that remains concentrated in large-scale health-care markets. Investors tracking the stock for dividend reliability will likely focus next on whether earnings and cash flow from Innovative Medicine and MedTech continue to support further annual increases.